Skip to content
Search

Latest Stories

EU court sets criteria for GSK case on 'pay-for-delay' deals in UK

The European Union's top court set criteria on Thursday (30 January) to resolve a dispute in Britain over deals GlaxoSmithKline (GSK) struck with rival drugmakers to delay the launch of generic drugs.

The court said these deals in themselves do not constitute a breach of competition rules but their impact needed to be assessed because they could harm competition.


The case will now go back to the UK Competition Appeal Tribunal for a final judgment on the appeals.

The ruling follows a reference to the EU court by the tribunal on a decision imposed by the Competition and Markets Authority (CMA) on various manufacturers of generic medicines and GSK.

In 2016 the CMA found that GSK had agreed to pay over £50 million to other generic suppliers of an antidepressant medicine paroxetine. The CMA contended that these payments were aimed at delaying the potential entry of competitors into the UK market.

Consequently, the regulator imposed fines of £45 million on the companies involved.

The CMA welcomed the ruling and said it has clarified a number of important questions and will help competition authorities in their work.

“This case shows our ongoing determination to take action against illegal behaviour by drug companies designed to stifle competition at the expense of the NHS. This has been a lengthy process, and we look forward to the CAT’s final judgment,” Andrea Coscelli, chief executive at the CMA, added.

Appeals against the CMA’s decision were brought by GSK, Generics (UK) Limited, Xellia Pharmaceuticals APS/Alpharma LLC, Actavis UK Limited and Merck KGAA.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less